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Abstract
Objective: To determine whether women delivering preterm have unfavorable cardio-
vascular profiles as compared with women who deliver at term.
Methods: A prospective observational cohort study enrolled 165 women with sponta-
neous preterm delivery (sPTD) at 24+0 and 36+6 gestational weeks in three perinatal 
care centers in The Netherlands between August 2012 and August 2014. Total cho-
lesterol, triglycerides, high- density lipoprotein (HDL)- cholesterol, low- density lipopro-
tein (LDL)- cholesterol, apolipoprotein, glucose, and homocysteine were measured 
within 24 hours after delivery. Lipids and cardiovascular biochemical risk factors were 
compared between women with sPTD and an external comparison group of 30 women 
with term delivery via analysis of covariance.
Results: Mean gestational age at delivery was 30.7 ± 3.6 weeks in the sPTD group and 
40.3 ± 1.3 weeks in the reference group. Data were adjusted for body mass index, age, 
and center. As compared with the reference group, total cholesterol and LDL- 
cholesterol levels were lower and glucose levels were higher among women with sPTD.
Conclusion: An association between sPTD and unfavorable lipids and cardiovascular 
biochemical risk factors was not established. The higher levels of glucose in the sPTD 
group might be due to increased insulin resistance, which is associated with a higher 
risk of sPTD.
K E Y W O R D S
Biochemical marker; Cardiovascular risk factors; Corticosteroids; Glucose; Hyperglycemia; 
Lipids; Preterm birth; Preterm delivery
1  | INTRODUCTION
Spontaneous preterm delivery (sPTD), defined as delivery before 37 
gestational weeks, is the leading cause of neonatal morbidity and 
mortality worldwide.1 It has a worldwide prevalence of 5%–13%, 
and affects approximately 12.9 million pregnancies annually.2 The 
burden of disease due to sPTD is associated with high expenditure 
for medical care, special education, and institutionalized care for 
disabled infants.
Two- thirds of preterm deliveries occur as a result of sponta-
neous labor or preterm pre- labor rupture of membranes (PPROM).3 
The mechanisms that initiate the inappropriate activation of uterine 
contractions and/or PPROM are largely unknown. Risk factors for 
sPTD include uterine overdistension (i.e., multiple gestations and 
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polyhydramnios), blood loss, previous sPTD, and infection, among 
others.3 Cardiovascular pathology has also gained interest as a risk 
factor for sPTD: women who deliver preterm with spontaneous 
onset have been shown to have increased risk of type 2 diabetes 
and cardiovascular disease later in life.4,5 The pathways that might 
link sPTD with this increased risk of maternal cardiovascular disease 
are not well understood. However, pregnancies are metabolically 
stressful and, if the woman is predisposed to cardiovascular disease, 
she might have a reduced ability to adapt appropriately to the ges-
tational vascular and metabolic changes that pregnancy induces, 
resulting in sPTD.
Over the past few years, several studies have tried to eluci-
date the relationship between sPTD and maternal lipid composi-
tion, homocysteine, and hyperglycemia6–8; however, they report 
conflicting results on the association between lipid levels and risk 
of sPTD. Moreover, the lipids were mainly measured before and in 
the first two trimesters of pregnancy. There are few data on lipids 
and other cardiovascular biochemical risk factors measured directly 
after delivery. This information might have the potential to clarify 
the mechanisms that initiate sPTD. The aim of the present study was 
to determine whether women who deliver preterm have unfavorable 
cardiovascular profiles shortly after delivery relative to women who 
deliver at term.
2  | MATERIALS AND METHODS
The PRELHUDE study (Preterm Labour; Heart and Vascular Defects), 
a prospective observational multicenter cohort study to explore car-
diac and vascular disease as a potential cause of sPTD, enrolled preg-
nant women with signs of threatening sPTD between August 1, 2012, 
and August 31, 2014, at three perinatal centers in The Netherlands: 
Academic Medical Center (AMC), Amsterdam; University Medical 
Center Groningen (UMCG), Groningen; and University Medical Center 
Utrecht (UMCU), Utrecht. The study protocol was approved by the 
ethics committee of the AMC (ref. no. MEC AMC 2011 299) and the 
management boards of all participating hospitals. All women provided 
written informed consent.
All women aged at least 18 years with a gestational age of 
24–37 weeks were invited to participate in the study. The exclu-
sion criteria were known HIV seropositivity, known maternal 
congenital heart disease, multiple pregnancy, uterine anomaly, 
and known fetal congenital or chromosomal anomaly. Women 
were  subsequently enrolled in the study if they delivered before 
37 weeks of gestation.
As a reference group, women with term delivery were selected 
from the Preeclampsia And Non- preeclampsia Database (PANDA; 
AMC approval ref. no. MEC AMC 05 133),9 which included 165 
women with gestational hypertensive disease and 268 women 
with non- hypertensive pregnancies attending AMC between 2005 
and 2010. The set- up and execution of PANDA conformed to the 
Dutch biobank regulations at that time. Maternal blood, umbilical 
cord blood, and placenta tissue combined with clinical information of 
the mother and neonate were stored with informed consent. Frozen 
plasma samples (−80 °C) were obtained at—or within 24 hours 
of—delivery.
Medical records were used to collect baseline data including 
demographic data (age, ethnicity); general medical history; medica-
tion; smoking (non- smoker, quit in first trimester, current smoker); 
obstetric history; length and weight before pregnancy; blood pres-
sure before 12 gestational weeks; PPROM; treatment with tocolytic 
medication; treatment with corticosteroids (first and second course); 
route of delivery; additional pregnancy complications; gestational age 
at delivery; delivery weight; and neonatal outcome. Body mass index 
(BMI, calculated as weight in kilograms divided by the square of height 
in meters) was calculated for each woman by using height and weight 
recorded before pregnancy. For all women, gestational age was cal-
culated on the basis of an ultrasound scan performed at 8+4 to 12+6 
gestational weeks.
The following pregnancy complications were defined: gestational 
diabetes mellitus (GDM; blood glucose, ≥6.1 mmol/L at fasting; and 
≥7.8 mmol/L after 75- g oral glucose tolerance test); pregnancy- 
induced hypertension (PIH; systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg in the absence of proteinuria, 
measured at two different times with an minimum interval of 4 hours, 
occurring for the first time after ≥20 gestational weeks) and pre- 
eclampsia (PIH with ≥0.3 g/24 hours proteinuria or PIH with protein/
creatine ratio ≥30 mg/mmol).
Blood samples were collected within 24 hours after delivery. 
The women did not routinely fast before sample collection because 
fasting has little impact on lipid levels.10 The following biomarkers 
were measured: total cholesterol, triglycerides, high- density lipopro-
tein cholesterol (HDL- c), low- density lipoprotein cholesterol (LDL- c), 
apolipoprotein B (ApoB), non- fasting glucose, and homocysteine. All 
blood samples were centrifuged immediately after collection and ana-
lyzed by standard procedures at the clinical chemistry laboratories 
of the three participating centers. Homocysteine specimens were 
placed on ice and transported to the laboratory within 30 minutes 
of collection.
At the AMC, total cholesterol, triglycerides, HDL- c, and glu-
cose were measured by a Cobas 8000 analyzer (Roche, Mannheim, 
Germany). ApoB was measured by an Architect C8000 analyzer (Abbott, 
Abbott Park, IL, USA). Homocysteine was measured by a Premier XE 
mass spectrometer (Waters, Milford, MA, USA). At the UMCG, total 
cholesterol, triglycerides, HDL- c, glucose, and LDL- c were measured 
by a Modular of Cobas chemical analyzer (Roche). ApoB was measured 
by a BN2 analyzer (Siemens Healthcare Nederland, The Hague, The 
Netherlands). Homocysteine was measured by an Architect analyzer 
(Abbott). At the UMCU, total cholesterol, triglycerides, HDL- c, LDL- 
c, ApoB, glucose, homocysteine were measured by a Vitros (Ortho, 
Mulgrave, Vic., Australia) or DxC800 (Beckman Coulter, Brea, CA, 
USA) analyzer. At all centers, LDL cholesterol was calculated by using 
the Friedewald formula. The same analyses were performed for the 
reference plasma samples at the UMCU.
Incomplete case analyses lead to loss of statistical power; there-
fore, the present analyses were first done without imputation of 
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missing covariates. Because no differences in data were found, miss-
ing values of key covariates in both groups (BMI, n=26; blood pres-
sure, n=44; current smoking, n=9; ethnicity, n=30), and missing data 
on lipids and other cardiovascular biochemical risk factors of the sPTD 
group (total cholesterol, n=1; LDL- c, n=4; ApoB, n=2; homocysteine, 
n=28; glucose, n=1) were imputed by using a multivariate normal 
imputation technique (10 imputation sets) in SPSS version 21.0 (IBM, 
Armonk, NY, USA).
All statistical analyses were performed by SPSS version 21.0. 
Baseline variables were expressed as mean ± SD or number (per-
centage) as appropriate. Lipid levels and biochemical cardiovascular 
indices were compared between the sPTD and reference group by 
analysis of covariance using the covariates age, BMI, and center, 
and are reported as mean (95% confidence interval). Subgroup 
analysis was conducted to compare administration of corticoste-
roids within the 2 days before delivery, administration of cortico-
steroids more than 2 days before delivery, and no administration 
of corticosteroids. The same analysis was repeated for a cut- off 
of 3, 4, and 5 days, because the glycemic effect of steroids begins 
approximately 12 hours after the first dose and lasts up to 5 days.11 
Subgroup analysis was also performed for mode of delivery (vagi-
nal vs cesarean), severity of PTD (24–30, 30–34, and 34–37 gesta-
tional weeks), and start of delivery (ruptured vs intact membranes). 
A  two- tailed P value of less than 0.05 was considered to be statis-
tically significant.
3  | RESULTS
During the 2- year study period, 188 women with sPTD met the 
study criteria and were enrolled in the study. Blood samples to 
assess lipids and other cardiovascular biochemical risk factors were 
subsequently available for 165 women, who were included in the 
final analysis. For the reference group, there were 81 normotensive 
singleton pregnancies for which three or more ampoules of frozen 
heparin plasma were available in the biobank; of these, 51 samples 
were excluded because of delivery before 37 or after 42 gestational 
weeks; cesarean delivery; multiple pregnancy; gestational diabe-
tes; drug usage; maternal heart disease; thrombophilia disorder or 
reported pre- existing maternal disease; congenital neonatal abnor-
malities; or insufficient clinical data to judge these criteria. Thus, 30 
reference samples were available and the frozen maternal plasma 
samples were obtained for the analysis of cardiovascular biochemical 
risk factors in the present study.
Baseline characteristics of the study and reference groups are 
summarized in Table 1. Intrinsic to the nature of the study groups, 
mean gestational age at delivery and delivery weight were differed 
between the two groups (both P<0.001). Most women in both groups 
were white (sPTD group, 81.8%; reference group, 83.3%).
Table 2 presents the crude and adjusted lipid levels and cardio-
vascular biochemical risk factors in the sPTD and reference groups. 
Women with sPTD had lower levels of cholesterol and LDL- c relative 
to the reference group. Glucose levels were significantly higher among 
women with sPTD, even after additional adjustment for administration 
of corticosteroids (data not shown).
Corticosteroids were administered to 132 (80%) women with 
sPTD, 14 of whom received a second course. In Table 3, levels of lipids 
and biochemical cardiovascular indices are stratified by women who 
received corticosteroids within the 2 days before delivery, those who 
received them more than 2 days before delivery, and those who did 
not receive these drugs. No differences were found between these 
groups. Similar results were found for a cut- off of 3, 4, and 5 days (data 
not shown).
For 33 women in the sPTD group, an emergency cesarean was per-
formed for reasons of fetal distress (n=21), non- vertex presentation 
(n=11), and prior cesarean delivery (n=1). There were no differences 
between women who delivered preterm by cesarean and those who 
delivered vaginally. Within the sPTD group, no significant differences 
were observed regarding the severity of PTD (24–30, 30–34, or 
34–37 gestational weeks) or status of membranes at start of delivery 
(ruptured or intact) (data not shown).
TABLE  1 Characteristics of the study women by presence of sPTD.a
Characteristic sPTD (n=165)
Reference 
group (n=30) P value
Maternal age, y 31.5 ± 5.3 29.8 ± 5.1 0.102
White 135 (81.8) 25 (83.3) 0.837
Pre- pregnancy 
BMI
23.7 ± 4.3 24.5 ± 5.5 0.173
Diabetes mellitus 4 (2.4) 0
Nulliparous 100 (60.6) 16 (53.3) 0.461
Smoking during 
pregnancy
20 (12.1) 3 (10) 0.393
Systolic BP at 
≤12 wk, mm Hg
112 ± 12 111 ± 11 0.380
Diastolic BP at 
≤12 wk, mm Hg
66 ± 9 65 ± 11 0.203
PPROM 70 (42.4) NA








Gestational age at 
delivery, d
215 ± 25 282 ± 9 <0.001
Delivery weight, g 1712 ± 704 3605 ± 440 <0.001
Cesarean delivery 33 (20.0) NA
Abbreviations: BMI, body mass index (calculated as weight in kilograms 
divided by the square of height in meters); DM, diabetes mellitus; BP, 
blood pressure; PPROM, preterm pre- labor rupture of membranes; PE, 
pre- eclampsia; PIH, pregnancy- induced hypertension; sPTD, spontaneous 
preterm delivery; NA, not applicable.
aValues are given as mean ± SD or number (percentage).
     |  209Heida eT aL.
4  | DISCUSSION
The main finding of the present study is that peripartum women with 
sPTD had lower levels of total cholesterol and LDL- c and higher levels 
of non- fasting glucose as compared with those who delivered vagi-
nally at term. However, the levels were within normal ranges. As a 
result, it was not possible to establish an association between sPTD 
and unfavorable lipids or biochemical cardiovascular indices. The dif-
ferences in lipids might be explained by the physiologic increase in 
lipids that occurs during pregnancy. The higher levels of glucose in the 
sPTD group were not attributed to the effect of corticosteroids: the 
difference might be explained by increased insulin resistance, which is 
associated with a higher risk of sPTD.12
To predict the risk of sPTD, other studies have examined lipid levels 
before and in the first two trimesters of pregnancy.6–8,13–17 Both the 
design and results of those studies differ from the present analysis. For 
example, three studies on pre- pregnancy14 and second- trimester7,15 
measurement of lipids found an association between increased lev-
els of total cholesterol and sPTD risk, although four other studies did 
not confirm this.8,13,16,17 No association was observed between risk of 
sPTD and HDL- c or LDL- c.6–8,13,14,16,17 The strongest association has 
been reported for high levels of homocysteine and sPTD measured 
at the second trimester8 and during delivery18; however, the current 
results indicate that this association does not persist shortly after 
delivery. In contrast to another study,19 the administration of cortico-
steroids did not seem to have an effect on levels of lipids or glucose in 
the present study.
Normal gestation is characterized by an increase in lipids in 
maternal circulation to ensure healthy fetal development.20 Owing to 
preterm delivery, lipid levels in the sPTD group were measured at an 
earlier stage of pregnancy relative to the reference group; thus, the 
lower levels of total cholesterol and LDL- c observed in the sPTD group 
might be the result of a smaller physiologic increase in lipids due to the 
shorter gestation.20
Gestational diabetes mellitus is associated with significantly 
increased risks of adverse perinatal outcomes.21 Milder hyperglycemia 
that does not meet the diagnostic criteria for GDM also amplifies the 
risk of adverse outcomes, including sPTD.12 Moreover, women with a 
history of sPTD have an increased risk of developing type 2 diabetes 
later in life.5 Consistent with this, women with sPTD had higher levels 
of glucose as compared with women who delivered at term, indepen-
dent of their BMI. Therefore, insulin resistance might play a role in 
TABLE  2 Comparison of cardiovascular biochemical risk factors between women with and those without sPTD.a
Risk factor
Crude analysis Adjusted analysisb
sPTD (n=165)
Reference group 
(n=30) P value sPTD (n=165)
Reference group 
(n=30) P value
Cholesterol, mmol/L 5.98 (5.78–6.19) 6.89 (6.40–7.37) 0.001 5.71 (5.44–5.99) 6.93 (6.45–7.41) <0.001
Triglycerides, mmol/L 2.29 (2.05–2.53) 2.52 (1.96–3.08) 0.453 2.04 (1.74–2.34 2.58 (2.02–3.13) 0.105
HDL- cholesterol, mmol/L 1.75 (1.68–1.81) 1.64 (1.50–1.79) 0.205 1.76 (1.68–1.84) 1.67 (1.53–1.82) 0.297
LDL- cholesterol, mmol/L 3.24 (3.07–3.42) 4.10 (3.69–4.52) <0.001 3.16 (2.92–3.39) 4.10 (3.68–4.51) <0.001
ApoB, g/L 1.20 (1.11–1.29) 1.36 (1.14–1.57) 0.194 1.17 (1.04–1.29) 1.35 (1.13–1.56) 0.172
Glucose, mmol/L 6.18 (5.91–6.45) 5.09 (4.45–5.72) 0.002 6.30 (5.95–6.66) 5.18 (4.56–5.80) 0.002
Homocysteine, μmol/L 6.07 (5.42–6.72) 7.39 (6.10–8.68) 0.082 5.82 (4.80–6.66) 7.22 (5.93–8.52) 0.120
Abbreviations: ApoB, apolipoprotein; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CI, confidence 
interval; HDL, high- density lipoprotein; LDL, low- density lipoprotein; sPTD, spontaneous preterm delivery.
aValues are given as mean (95% confidence interval).
bAdjusted for age, BMI, and center.
TABLE  3 Cardiovascular biochemical risk factors among women with sPTD by the interval between corticosteroid administration and delivery.a
Risk factor ≤2 d CCS (n=64) >2 d CCS (n=68) P value No CCS (n=33) P valueb
Cholesterol, mmol/L 5.92 (5.48–6.35) 5.47 (5.06–5.89) 0.136 5.85 (4.90–6.79) 0.937
Triglycerides, mmol/L 1.96 (1.39–2.52) 2.01 (1.47–2.56) 0.889 2.36 (1.78–2.93) 0.149
HDL- cholesterol, mmol/L 1.85 (1.73–1.97) 1.72 (1.60–1.83) 0.118 1.84 (1.57–2.10) 0.781
LDL- cholesterol, mmol/L 3.33 (2.95–3.70) 2.95 (2.59–3.31) 0.157 3.12 (2.29–3.94) 0.658
ApoB, g/L 1.16 (0.94–1.38) 1.16 (0.94–1.37) 0.954 1.17 (0.95–1.39) 0.880
Glucose, mmol/L 6.17 (5.62–6.73) 6.20 (5.67–6.74) 0.933 6.59 (5.24–7.94) 0.546
Homocysteine, μmol/L 6.59 (5.10–8.08) 5.40 (3.89–6.91) 0.199 4.90 (1.50–8.31) 0.353
Abbreviations: ApoB, apolipoprotein B; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CI, confidence 
interval; CCS, corticosteroid administration; HDL, high- density lipoprotein; LDL, low- density lipoprotein; sPTD, spontaneous preterm delivery.
aAdjusted for age, BMI, and center.
bVersus ≤2 d CCS.
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the pathogenesis of sPTD in the present cohort and should be fur-
ther studied. However, mechanisms by which insulin resistance might 
increase the risk of sPTD have not been elucidated.
The strengths of the study include its prospective design and 
inclusion of BMI as a confounder in the analysis. Nonetheless, some 
limitations must be considered. First, lipids were not measured in fast-
ing samples, which might have influenced the levels observed. On the 
one hand, studies comparing fasting with non- fasting lipid levels show 
minimal differences (<5%) for total cholesterol, HDL- c, and LDL- c val-
ues, although triglycerides may be increased by 15% in the non- fasted 
state.10 On the other hand, non- fasting lipids may more appropriately 
reflect the physiologically relevant exposure.
Second, the term delivery group was relatively small and com-
prised women from another cohort with a different study protocol, 
in which samples were stored at −80 °C prior to analysis. Storage 
might lead to an underestimation of total cholesterol and tri-
glycerides and an overestimation of HDL- c.22 If this is true for the 
present data, the differences between the lipid levels of the sPTD 
and reference group would increase, but the conclusions would 
remain the same.
Third, because the etiology or sPTD is multifactorial, the effect of 
different mechanisms of preterm delivery, such as infection, on lipid 
levels and other biochemical cardiovascular risk factors was not stud-
ied in the present cohort. However, there was no difference between 
women with PPROM, which is associated with infection, and those 
who presented with intact membranes and contractions.
Fourth, a power analysis was not carried out because the 
PRELHUDE study was essentially a cohort study. Therefore, it is not 
clear whether the study was sufficiently powered enough to show a 
significant difference between the groups. Last, lipids were measured 
in the first 24 hours after delivery, and lipid levels decrease signifi-
cantly in this period.23 Although the levels of lipids reported possibly 
do not fully reflect late pregnancy levels, the decrease is likely to be 
similar in the sPTD and reference groups because sampling was per-
formed in the first 24 hours after delivery in both groups.
In summary, the present results indicate a more favorable maternal 
cardiovascular lipid profile shortly after delivery in women with sPTD 
as compared with women with a term delivery. These differences 
might be explained by the physiologic increase in lipids that occurs 
during pregnancy. As a result, the previously reported association 
between sPTD and cardiovascular biochemical risk factors cannot be 
confirmed. Insulin resistance might play a role in the pathogenesis of 
sPTD and should be further studied.
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